Hepatoprotectors Hep-A-Stress and Hepasan-VS for the treatment and prevention of hepatitis in laying hens.

Abstract

This article reports on the effectiveness of the hepatoprotectors Hep-A-Stress and Hepasan-VS in preventing hepatosis in laying hens. The study took
place in a state-of-the-art chicken farm. Lohmann Brown laying hens (n = 1500) were split into three groups (control, experimental, and
observational) at the age of 224 days. The birds were fed a primary diet designed for this breed, as outlined in a technical road map. The first group of
laying hens in the trial received the hepatoprotective drug Hep-A-Stress, whereas the second group received the drug Hepasan-VS. For the trial, blood
was taken three times: once before the commencement of medication administration, once 10 days into treatment, and once 30 days into treatment
with hepatorotectors. Research into the long-term viability and output of chickens, as well as the interpretation of biochemical analyses of blood
serum, helped establish the preventive impact of these medications. Hepato-protectors have helped laying chickens live longer and produce more eggs.
Our research revealed that hepatoprotectors have a sluggish impact on the regenerating processes in the body of poultry, with the findings showing
minimal alterations of biochemical markers in blood after 10 days of administration of medications. After 30 days of using hepatoprotectors, their
preventative value was established. We found that the blood total protein level dropped and the albumin level rose after treatment with these
medications, suggesting a beneficial impact on the liver's protein-synthesizing capacity. Positive effects on the rate of protein metabolism were also
seen, as measured by lower levels of uric acid and higher levels of urea in the serum of the experimental groups. The enzymes AST and ALT are
unique to the liver, and their decreased activity after treatment with hepato-protectors suggests that the hepatocytes' cellular structures have been
stabilized. An rise in serum cholesterol levels is indication that these medications have boosted the function of bile secretion, a critical step in lipid
metabolism. By normalizing liver function and preventing the formation of hepatosis, the administration of these hepatoprotectors has a beneficial
influence on metabolic processes in the bodies of laying hens.